Beranda › Limfoma Sel Mantel › California

Uji klinis Limfoma Sel Mantel di California

29 studi untuk Limfoma Sel Mantel mencari peserta di lokasi di California.

Kota di California

Teks studi resmi (Bahasa Inggris)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Tower Cancer Research Foundation, Beverly Hills
Cedars-Sinai Medical Center, Los Angeles

Menerima pesertaFase 3

Usia 60 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05976763

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis, Davis
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
dan 1 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06252675

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Ucsf Fresno, Fresno
Kaiser Permanente Southern California, Irvine

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Stanford Cancer Center, Stanford

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06553872

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

City of Hope Comprehensive Cancer Center, Duarte

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07003295

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07691606

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06340737

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

Menerima pesertaFase 1

Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT05887167

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Menerima pesertaFase 1/2

Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06675123

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07121946

DALY II USA/ MB-CART2019.1 for DLBCL

UC San Diego Health, La Jolla
Stanford University, Stanford

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT04545762

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center, Duarte

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT03523975

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
dan 1 lainnya

Menerima pesertaFase 1/2

Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT04830137

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06572618

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Feb 2026 · NCT05432635

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jan 2026 · NCT06054776

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

City of Hope Medical Center, Duarte
Stanford University, Stanford

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Nov 2025 · NCT05370430

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
dan 3 lainnya

Menerima pesertaStudi observasional

Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Agu 2024 · NCT05255354

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.